Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficilein vitro.

CONCLUSION: The ability of fidaxomicin to suppress early exotoxin production and endospore formation by historical and epidemic strains of C. difficile may explain its clinical success in treating severe and recurrent cases of CDI disease. PMID: 28893366 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28893366?dopt=Abstract

Source: Journal of Medical Microbiology - September 12, 2017 Category: Microbiology Authors: Aldape MJ, Packham AE, Heeney DD, Rice SN, Bryant AE, Stevens DL Tags: J Med Microbiol Source Type: research